Faculty of Medicine, Nursing, and Health Sciences, Monash University, Clayton, Victoria, Australia.
Monash Infectious Diseases, Monash Health, Clayton, Victoria, Australia.
Clin Infect Dis. 2024 Oct 15;79(4):848-854. doi: 10.1093/cid/ciae302.
Suppressive antibiotic therapy is prescribed when a patient has an infection that is presumed to be incurable by a defined course of therapy or source control. The cohort receiving suppressive antibiotic therapy is typically highly comorbid and the infections often involve retained prosthetic material. In part due to a lack of clear guidelines regarding the use of suppressive antibiotics, and in part due to the complex nature of the infections in question, patients are often prescribed suppressive antibiotics for extremely long, if not indefinite, courses. The risks of prolonged antibiotic exposure in this context are not fully characterized, but they include adverse drug effects ranging from mild to severe, the development of antibiotic-resistant organisms, and perturbations of the gastrointestinal microbiome. In this narrative review we present the available evidence for the use of suppressive antibiotic therapy in 4 common indications, examine the gaps in the current literature, and explore the known and potential risks of this therapy. We also make suggestions for improving the quality of evidence in future studies, particularly by highlighting the need for a standardized term to describe the use of long courses of antibiotics to suppress hard-to-treat infections.
当患者的感染预计无法通过既定疗程或源头控制治愈时,会开具抑制性抗生素治疗。接受抑制性抗生素治疗的患者通常合并症较多,感染通常涉及残留的假体材料。部分由于缺乏关于使用抑制性抗生素的明确指南,部分由于所涉及感染的复杂性,患者通常会接受极长(如果不是无限期)的抑制性抗生素治疗。在这种情况下,长期使用抗生素的风险尚未完全明确,但包括从轻度到重度的药物不良反应、抗生素耐药菌的产生以及胃肠道微生物组的紊乱。在这篇叙述性综述中,我们介绍了抑制性抗生素治疗在 4 种常见适应证中的应用的现有证据,考察了当前文献中的空白,并探讨了这种治疗方法的已知和潜在风险。我们还为未来研究提高证据质量提出了建议,特别是通过强调需要一个标准化的术语来描述使用长疗程抗生素抑制难治性感染的情况。